Bliss GVS Pharma Limited (BOM:506197)
India · Delayed Price · Currency is INR | Market Cap | 28.29B +125.5% |
| Revenue (ttm) | 8.68B +7.2% |
| Net Income | 1.09B +83.0% |
| EPS | 10.19 +81.2% |
| Shares Out | 105.79M |
| PE Ratio | 26.24 |
| Forward PE | n/a |
| Dividend | 1.00 (0.37%) |
| Ex-Dividend Date | Feb 18, 2026 |
| Volume | 20,702 |
| Average Volume | 78,072 |
| Open | 274.40 |
| Previous Close | 274.40 |
| Day's Range | 269.00 - 277.20 |
| 52-Week Range | 105.05 - 280.20 |
| Beta | 0.95 |
| RSI | 59.32 |
| Earnings Date | May 12, 2026 |
About Bliss GVS Pharma
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provide... [Read more]
Financial Performance
In fiscal year 2025, Bliss GVS Pharma's revenue was 8.10 billion, an increase of 5.13% compared to the previous year's 7.70 billion. Earnings were 842.99 million, an increase of 11.72%.
Financial StatementsNews
Bliss GVS Pharma shares fall over 15% today as EBITDA drops 20% and margins shrink to 13%
Friday, November 7: Shares of Bliss GVS Pharma Ltd declined sharply by 15.8% to Rs 127.94 in early trade after...
Bliss GVS Pharma Q2 results: Net profit up 2.5% to Rs 25.69 crore; EBITDA down 20%, margin contracts to 13%
Friday, November 7: Bliss GVS Pharma Ltd reported a modest performance for the quarter ended September 30, 2025, with revenue...
Bliss GVS Clarifies USFDA ANDA Approval for Mesalamine Suppositories
Bliss GVS Pharma Limited has issued an official clarification confirming that its marketing and distribution partner in the United States, Rising Pharma Holdings Inc., has received final approval from...
Bliss GVS Pharma shares surge 4% after company receives GMP Compliance certification for its manufacturing facilities in Palghar
Bliss GVS Pharma’s stock rose 4% in morning trade after the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This certification was granted after a rigorous inspection by R...
Bliss GVS Pharma receives GMP Compliance certification for manufacturing facilities in Palghar, Maharashtra
Bliss GVS Pharma Limited has recently informed exchanges that the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This recognition comes after a comprehensive inspection c...